Analysis of differential metabolites in lung cancer patients based on metabolomics and bioinformatics

Future Oncol. 2020 Jun;16(18):1269-1287. doi: 10.2217/fon-2019-0818. Epub 2020 May 1.

Abstract

Aim: Based on metabonomics, the metabolic markers of lung cancer patients were analyzed, combined with bioinformatics to explore the underlying disease mechanism. Materials & methods: Based on case-control design, using UPLC-Q-TOF/MS, urine metabolites were detected in discovery and validation set. Multivariate statistical analysis were performed to identify potential markers for lung cancer. A network analysis was constructed to integrate lung cancer disease targets with the above metabolic markers, and its possible mechanism and biological significance were explained. Results: A total of 35 potential markers were identified, 11 of which overlapped. Five key markers have a good linear correlation with serum biochemical indicators. Conclusion: The occurrence and development of lung cancer are closely related to disturbance of D-Glutamine and D-glutamate metabolism, amino acid imbalance. This test was registered on China clinical trial registration center (www.chictr.org.cn/index.aspx), registration number was ChiCTR1900025543.

Keywords: ROC curve; UPLC-Q-TOF/HRMSE; bioinformatics; case–control design; clinical metabolomics; lung cancer; metabolic markers; qualitative analysis; spearman correlation; urine.

MeSH terms

  • Aged
  • Biomarkers
  • Case-Control Studies
  • Chromatography, High Pressure Liquid
  • Computational Biology* / methods
  • Databases, Factual
  • Energy Metabolism*
  • Female
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / urine
  • Male
  • Metabolome*
  • Metabolomics* / methods
  • Middle Aged
  • ROC Curve
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Substances

  • Biomarkers